In a prospective randomized study, ceftazidime monotherapy was compared with a combination of ceftazidime plus cephalothin in 102 febrile neutropenic patienits. Thirty bacteriologically documnented infections, of which 23 were bacteremias, in 48 clinically assessable patients were treated with ceftazidime alone. Twenty-four bacteriologically proven infections, of which 18 were bacteremias, in 42 clinically assessable patients were treated with a combination of ceftazidime and cephalothin. The clinical response rates in assessable patients were 77% for ceftazidime monotherapy and 88% for the combination. The bacteriological clearance rate was 70% for ceftazidime monotherapy and 79% for the combination. Efficacy against gram-negative pathogens appeared to be excellent, with 93% clearance for ceftazidime monotherapy and 100% clearance for the combination. The bacteriological clearance of gram-positive infections was only 60% for both regimens, with failures mainly due to Streptococcus faecalis and Streptococcus sanguis, which are primnarily resistant to both ceftazidime and cephalothin. After addition of rancomycin to those infections which did not respond to empiric therapy, bacteriological clearance rates of 94% (ceftazidime plus vancomycin) and 90% (ceftazidime and cephalothin plus vancomycin) were achieved. Three superinfections were registered in the ceftazidime group and two were seen in the combination group. Other adverse effects of ceftazidime were minimal and were not enhanced by combination with cephalothin. It is conciuded that ceftazidime is an effective drug for the empiric treatment of febrile neutropenic patients, especially if one is prepared to modify therapy if resistant gram-positive strains or mycotic infections are encountered. Neither the clinical nor bacteriological cure rates could be substantially improved by adding cephalothin to ceftazidime in initial empiric treatment of febrile neutropenic patients.
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Despite substantial improvement in supportive care, infection remains the major cause of morbidity and mortality in patients with bone marrow failure secondary to malignant diseases or cytotoxic treatment. Early institution of empiric antibiotic therapy has become standard practice for the initial management of febrile episodes in neutropenic patients. Synergistic schedules consisting of two or three drugs, including aminoglycosides, have been used, and early death due to inadequately treated bacterial infections has been largely overcome. However, concern for nephrotoxicity and ototoxicity can limit the use of aminoglycosidecontaining schedules, especially in the growing group of patients treated concomitantly with other potentially nephrotoxic drugs such as amphotericin B , cis-platinum, and cyclosporin A. Ceftazidirne, in view of its excellent gramnegative spectrum in vitro (10, 13) , was shown to be comparable to the established aminoglycoside-containing schedules in different studies, as reviewed by Pizzo et al. (12) , and offers the opportunity of monotherapy in the febrile neutropenic patient.
We have previously assessed the role of ceftazidime as empiric mnonotherapy for febrile episodes in granulocytopenic patients in two randomized comparative trials. In the first study (3) , ceftazidime was shown to be significantly * Corresponding author.
superior to a combination of gentamicin and cefotaxime. B3ecause of the lesser activity of ceftazidime against grampositive infections, we were forced to modify the initial ceftazidime monotherapy in a small subgroup of patients. In the second comparative trial (4), flucloxacillin in combination with ceftazidime did not improve the efficacy of ceftazidime monotherapy. This was partly due to gram-positive organisms found to be initially resistant to both drugs, partly caused by emerging resistance to flucloxacillin, and to more superinfections in the group treated with the combination schedule. Patients who failed to respond to ceftazidime alone or to the combination with flucloxacillin were switched successfully to the combination of ceftazidime plus cephalothin. Hence, it was decided to compare a combination of ceftazidime plus cephalothin with ceftazidime alone prospectively. Furthermore, it was not possible to evaluate the combination of vancomycin plus ceftazidime as both were investigational drugs in The Netherlands at that time. The actual study protocol was agreed upon by the local ethics committee.
MATERIALS AND METHODS
This study was 6 7 Malignant lymphoma 6 5 Aplastic anemia 5 4 Solid tumors 7 8 (Patients with bone marrow (11) (4). Pretreatment evaluation included a complete history, physical examination, and cultures from the blood, urine, mouth, nose, throat, sputum, and any clinically suspicious lesion. Antimicrobial disk susceptibility testing was done according to the Kirby-Bauer method (1). Disks containing 30 jig of ceftazidime were used. Laboratory investigation included hemoglobin and hematocrit, thrombocyte count, leukocyte count and differential, serum creatinine, glutamicoxalacetic transaminase, glutamic pyruvic transaminase, and urinalysis, which were performed as previously described (4).
After informed consent was obtained, the patients were randomly allocated to receive either ceftazidime alone (2 g intravenously every 8 h) or a combination of ceftazidime (2 g intravenously every 8 h) and cephalothin (2 g intravenously every 6 h), all as 30-min infusions. When systemic therapy was started, selective gut decontamination was terminated except for the antifungal compound. The empiric therapy was evaluated at 72 h and modified or substituted only if the patient had not responded, unless adverse reactions or isolation of a pathogen resistant to the antibiotic(s) administered in the presence of a deteriorating clinical status urged an earlier change in therapy. In general, therapy was continued until the patient was free of symptoms of infection for 4 infections. Underlying disease, degree of granulocytopenia, mean age, and weight were evenly matched in both study groups. The proportion of women was higher in the ceftazidime monotherapy group than in the group with combination therapy, but the difference was not significant (Table 1) . Fifty-one patients were allocated to each study group. (See flow chart [ Fig. 1 ].) Three patients in the ceftazidime group (two fungal infections, one drug fever) and nine patients treated with cefazidime plus cephalothin (two proven viral infections, six fungal infections, one drug fever) were unassessable for response. Details of the unassessable patients are summarized in Table 2 . The results of treatment are shown in Tables 3 and 4 . Initial empiric therapy was successsful in keeping alive 96% of patients treated with ceftazidime monotherapy when evaluated after 72 h of therapy. One patient with a positive blood culture of Escherichia coli was admitted in septic shock and died after only one dose of ceftazidime, and one patient treated with ceftazidime monotherapy died on day 3 due to Candida pneumonitis, confirmed at autopsy. For ceftazidime plus cephalothin the initial empiric therapy, evaluated at 72 h, was successful in the prevention of early fatal outcome in 98% of the patients. One patient with gastric carcinoma and paralytic ileus developed a Candida albicans plus E. coli septicemia and died on day 3 of treatment due to persisting shock.
Although the data are not shown, ceftazidime as empiric monotherapy was successful in 72% of all cases (including assessable and unassessable patients), with a return of temperature and clinical conditions to normal; a further 14% responded to additional antibiotics, and 2% responded to antifungal agents. Thirty-seven of 51 (72%) febrile episodes treated with ceftazidime plus cephalothin responded clinically, a further 6% responded after the addition of other antibacterial agents, and 6% responded after addition of antifungal agents. Analysis of only the assessable cases showed that 37 (77%) of 48 patients were successfully treated with ceftazidime alone, and a further 15% responded to additional antibiotics. Ceftazidime plus cephalothin as empiric therapy was successful in 37 (88%) of 42 clinically assessable patients, and a further 7% responded to additional antibiotics.
In the ceftazidime group, 30 of 48 assessable patients had bacteriologically documented infections; 21 (70%) of 30 responded to monotherapy. One patient died due to myocardial infarction on day 4 without signs of infection or positive cultures at autopsy. Although a bacteriological success, this patient was regarded as a clinical failure. Seven patients responded to modification with vancomycin, all with infections due to gram-positive organisms, and two were failures despite modification. Of 42 assessable patients treated with ceftazidime plus cephalothin, 24 had bacteriologically documented infections. Nineteen (79%) responded to the initial therapy and three responded after modification.
The bacteriological results, based on positive cultures obtained before treatment, are shown in Table 5 . There were no differences between the study groups. Twelve of 20 gram-positive organisms were eradicated by ceftazidime alone and 8 of 14 were eliminated by ceftazidime plus cephalothin. All but one gram-negative organism were eradicated by ceftazidime monotherapy, and all were eradicated by the combination therapy. A bacteriological clearance was achieved in 25 of 34 (74%) assessable initial isolates by ceftazidime alone. In 24 of 30 (80%) cases, the causative organisms were eradicated by ceftazidime plus cephalothin.
Seventeen of the 18 (94%) assessable, bacteriologically undocumented infections were cured with ceftazidime alone; one patient died due to massive gastrointestinal bleeding after initial improvement. All 18 (100%) assessable patients with bacteriologically undocumented infections responded to the combination therapy without modification.
At the time of response the majority of the successfully treated patients were still profoundly neutropenic (Table 3 ).
Twenty (54%) patients had <250 granulocytes per mm3, compared with 15 (40%) in the ceftazidime-plus-cephalothin group. None of the successfully treated patients showed an increase in neutrophil count of 1,000/mm3.
During ceftazidime monotherapy, three superinfections were registered: one Staphylococcus epidermidis, one Staphylococcus aureus, and one Candida albicans, all organisms resistant to ceftazidime. In two patients who received ceftazidime plus cephalothin, superinfections with orga- Table 2 ).
nisms resistant to both drugs occurred: one Clostridium difficile and one Candida albicans. One patient treated with ceftazidime alone suffered from drug fever and a skin rash, while two more patients developed exanthema. One patient treated with ceftazidime plus cephalothin showed a transient rise in glutamic oxalacetic and glutamic pyruvic transaminases. None of the patients had any sign of nephrotoxicity, as measured by serum creatinine levels, or ototoxicity. No local reactions to the drugs were seen.
DISCUSSION
The data from this study and others (3) (4) (5) (6) 11) show that ceftazidime alone or in combination with another antibacterial agent gives excellent coverage against gram-negative infections in the immunocompromised host, a prerequisite for any empiric treatment in this patient group (12 Concern has been expressed about double beta-lactam therapy in the immunocompromised host, especially about inducing beta-lactamase and resistance to gram-negative microorganisms (14) or resistance against a beta-lactamasesusceptible compound (7) . Ceftazidime has proven to be a weak beta-lactamase inducer (9) . The numbers of infecting strains are usually low in neutropenic patients, so it is less likely that stable derepressed mutants will be encountered. In this study there was no evidence of reduced susceptibility in the double beta-lactam combination against gram-negative organisms. Neither in the previous study, in which cephalothin served as a rescue scheme for the treatment of infections caused by gram-positive organisms resistant ceftazidime (4), nor in this study was induction of resistance observed. The only failures were due to primarily resistant strains.
Toxicity of ceftazidime was minimal, according to data from the literature (8) ; no aggravation of toxicity was seen in combination with cephalothin in this study.
In conclusion, the combination of ceftazidime with an antistaphylococcal penicillin (4) , aminoglycoside (6), or cephalothin did not improve the results with ceftazidime alone. Ceftazidime seems to be a safe and effective drug for monotherapy in the immunocompromised host, offering the opportunity to avoid the aminoglycosides and their inherent nephrotoxicity and ototoxicity. However, with monotherapy one should be prepared to modify therapy if resistant grampositive strains or mycotic infections are encountered.
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